SPATA18 Expression Predicts Favorable Clinical Outcome in Colorectal Cancer.
SPATA18 Expression Predicts Favorable Clinical Outcome in Colorectal Cancer.
复制标题
DOI：
10.3390/ijms23052753
复制
发表时间：
2022-03-02
影响因子：
5.6
通讯作者：
Inaguma S
中科院分区：
文献类型：
--
作者：
Sugimura-Nagata A;Koshino A;Nagao K;Nagano A;Komura M;Ueki A;Ebi M;Ogasawara N;Tsuzuki T;Kasai K;Takahashi S;Kasugai K;Inaguma S
据报道，线粒体质量控制的失调与癌症和退行性疾病有关。SPATA18(精子发生相关蛋白18，也称为MIEAP)编码一种P53诱导的蛋白，可诱导线粒体内的溶酶体样细胞器消除氧化的线粒体蛋白，并在线粒体质量控制中具有肿瘤抑制功能。在本研究中，我们用免疫组织化学方法检测了268例原发结直肠癌(CRC)中SPATA18的表达，以评估其预测价值及其与细胞增殖活性的关系。此外，还分析了TP53突变的替代标记物P53免疫反应与P53的关系。非肿瘤性结肠黏膜SPATA18呈胞浆表达。72%(193/268)的癌组织SPATA18高表达于结直肠癌细胞胞浆。单变量分析显示，SPATA18的表达与肿瘤大小(p<；0.0001)、组织分化(p=0.0017)和淋巴结转移(p=0.00039)显著相关。对数等级检验显示，SPATA18高表达患者的生存率显著高于低SPATA18表达患者(p<；0.0001)。多变量COX风险回归分析确定肾小管形成组织学(风险比[HR]=0.25)、年龄和年龄(HR=0.50)和SPATA18-HIGH(HR=0.55)是潜在的有利因素。淋巴结转移(HR=1.98)和腹膜转移(HR=5.45)是潜在的独立危险因素。在SPATA18高表达的肿瘤中，细胞增殖活性明显增强。然而，SPATA18的表达与P53免疫反应性和KRAS/BRAF突变状态无明显相关性。根据我们的观察，SPATA18免疫组织化学可以用来预测结直肠癌患者的预后。
Dysregulation of mitochondrial quality control has been reported to be associated with cancer and degenerative diseases. SPATA18 (spermatogenesis-associated 18, also known as Mieap) encodes a p53-inducible protein that can induce lysosome-like organelles within mitochondria that eliminate oxidized mitochondrial proteins and has tumor suppressor functions in mitochondrial quality control. In the present study, 268 primary colorectal cancers (CRCs) were evaluated immunohistochemically for SPATA18 expression to assess its predictive utility and its association with cellular proliferation activity. Furthermore, the association with p53 immunoreactivity, a surrogate marker for TP53 mutation, was analyzed. Non-neoplastic colonic mucosa showed cytoplasmic SPATA18 expression. Seventy-two percent of the lesions (193/268) displayed high SPATA18 expression in the cytoplasm of CRC cells. Univariate analyses revealed significant associations between SPATA18 expression and tumor size (p < 0.0001), histological differentiation (p = 0.0017), and lymph node metastasis (p = 0.00039). The log-rank test revealed that patients with SPATA18-high CRCs had significantly better survival than SPATA18-low patients (p < 0.0001). Multivariate Cox hazards regression analysis identified tubular-forming histology (hazard ratio [HR] = 0.25), age < 70 years (HR = 0.50), and SPATA18-high (HR = 0.55) as potential favorable factors. Lymph node metastasis (HR = 1.98) and peritoneal metastasis (HR = 5.45) were cited as potential independent risk factors. Cellular proliferation activity was significantly higher in SPATA18-high tumors. However, no significant correlation was detected between SPATA18 expression and p53 immunoreactivity or KRAS/BRAF mutation status. On the basis of our observations, SPATA18 immunohistochemistry can be used in the prognostication of CRC patients.
登录
查看更多内容
影响因子：
5.6
作者：
Koshino A;Nagano A;Ota A;Hyodo T;Ueki A;Komura M;Sugimura-Nagata A;Ebi M;Ogasawara N;Kasai K;Hosokawa Y;Kasugai K;Takahashi S;Inaguma S
通讯作者：
Inaguma S
对医疗统计信息的自由使用的易于使用的软件“ EZR”的调查。
影响因子：
4.8
作者：
Kanda Y
通讯作者：
Kanda Y
影响因子：
4.7
作者：
Fenqi D;Yupeng L;Qiuju Z;Chao Y;Wenjie S;Tianyi X;Junnan G;Weinan X;Xiufeng J;Junge B;Chenyang J;Hua X;Yien L;Xuefeng B;Yanlong L
通讯作者：
Yanlong L
线粒体内可能存在溶酶体样细胞器及其在线粒体质量控制中的作用。
影响因子：
3.7
作者：
Miyamoto Y;Kitamura N;Nakamura Y;Futamura M;Miyamoto T;Yoshida M;Ono M;Ichinose S;Arakawa H
通讯作者：
Arakawa H
影响因子：
16
作者：
Kashatus, Jennifer A.;Nascimento, Aldo;Myers, Lindsey J.;Sher, Annie;Byrne, Frances L.;Hoehn, Kyle L.;Counter, Christopher M.;Kashatus, David F.
通讯作者：
Kashatus, David F.